186 related articles for article (PubMed ID: 25695660)
1. Correction: Thymosin beta 4 protects mice from monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy.
PLOS ONE Staff
PLoS One; 2015; 10(2):e0118428. PubMed ID: 25695660
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of olmesartan medoxomil in the rat monocrotaline model of pulmonary hypertension.
Kato T; Nasu T; Sonoda H; Ito KM; Ikeda M; Ito K
J Cardiovasc Pharmacol; 2008 Jan; 51(1):18-23. PubMed ID: 18209564
[TBL] [Abstract][Full Text] [Related]
3. Correction: A phenotype of increased sleepiness in a mouse model of pulmonary hypertension and right ventricular hypertrophy.
Davis EM; Baust JJ; O'Donnell BJ; Shah FA; McDowell A; Guo L; O'Donnell CP
PLoS One; 2019; 14(6):e0218401. PubMed ID: 31181114
[TBL] [Abstract][Full Text] [Related]
4. Preventive effects of raloxifene, a selective estrogen receptor modulator, on monocrotaline-induced pulmonary hypertension in intact and ovariectomized female rats.
Nishida M; Hasegawa Y; Tanida I; Nakagawa E; Inaji H; Ohkita M; Matsumura Y
Eur J Pharmacol; 2009 Jul; 614(1-3):70-6. PubMed ID: 19379725
[TBL] [Abstract][Full Text] [Related]
5. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.
Schäfer S; Ellinghaus P; Janssen W; Kramer F; Lustig K; Milting H; Kast R; Klein M
Cardiovasc Res; 2009 Apr; 82(1):30-9. PubMed ID: 19131365
[TBL] [Abstract][Full Text] [Related]
6. Myocardial and anti-inflammatory effects of chronic bosentan therapy in monocrotaline-induced pulmonary hypertension.
Fontoura D; Oliveira-Pinto J; Tavares-Silva M; Leite S; Vasques-Nóvoa F; Mendes-Ferreira P; Lourenço AP; Leite-Moreira AF
Rev Port Cardiol; 2014 Apr; 33(4):213-22. PubMed ID: 24780128
[TBL] [Abstract][Full Text] [Related]
7. Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy.
Jasmin JF; Mercier I; Dupuis J; Tanowitz HB; Lisanti MP
Circulation; 2006 Aug; 114(9):912-20. PubMed ID: 16940204
[TBL] [Abstract][Full Text] [Related]
8. [Preventive effects of tetrandrine on pulmonary hypertension and right ventricular hypertrophy in rats induced by monocrotaline].
Jin X; Zhang X; Xing J; Liu K; Wang H
Zhongguo Zhong Yao Za Zhi; 1996 Dec; 21(12):751-2, 763. PubMed ID: 9812685
[TBL] [Abstract][Full Text] [Related]
9. Endogenous endothelin-1 mediates cardiac hypertrophy and switching of myosin heavy chain gene expression in rat ventricular myocardium.
Ichikawa KI; Hidai C; Okuda C; Kimata SI; Matsuoka R; Hosoda S; Quertermous T; Kawana M
J Am Coll Cardiol; 1996 Apr; 27(5):1286-91. PubMed ID: 8609357
[TBL] [Abstract][Full Text] [Related]
10. Impact of dietary iron restriction on the development of monocrotaline-induced pulmonary vascular remodeling and right ventricular failure in rats.
Naito Y; Hosokawa M; Hao H; Sawada H; Hirotani S; Iwasaku T; Okuhara Y; Eguchi A; Hirota S; Ohyanagi M; Tsujino T; Masuyama T
Biochem Biophys Res Commun; 2013 Jun; 436(2):145-51. PubMed ID: 23707944
[TBL] [Abstract][Full Text] [Related]
11. Genistein, a phytoestrogen, attenuates monocrotaline-induced pulmonary hypertension.
Homma N; Morio Y; Takahashi H; Yamamoto A; Suzuki T; Sato K; Muramatsu M; Fukuchi Y
Respiration; 2006; 73(1):105-12. PubMed ID: 16432296
[TBL] [Abstract][Full Text] [Related]
12. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats.
Porvasnik SL; Germain S; Embury J; Gannon KS; Jacques V; Murray J; Byrne BJ; Shacham S; Al-Mousily F
J Pharmacol Exp Ther; 2010 Aug; 334(2):364-72. PubMed ID: 20430844
[TBL] [Abstract][Full Text] [Related]
13. Effect of methylprednisolone on monocrotaline-induced pulmonary vascular disease and right ventricular hypertrophy.
Langleben D; Reid LM
Lab Invest; 1985 Mar; 52(3):298-303. PubMed ID: 3156262
[TBL] [Abstract][Full Text] [Related]
14. The effects of gender difference on monocrotaline-induced pulmonary hypertension in rats.
Bal E; Ilgin S; Atli O; Ergun B; Sirmagul B
Hum Exp Toxicol; 2013 Jul; 32(7):766-74. PubMed ID: 23821593
[TBL] [Abstract][Full Text] [Related]
15. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension.
Schermuly RT; Kreisselmeier KP; Ghofrani HA; Samidurai A; Pullamsetti S; Weissmann N; Schudt C; Ermert L; Seeger W; Grimminger F
Circ Res; 2004 Apr; 94(8):1101-8. PubMed ID: 15031263
[TBL] [Abstract][Full Text] [Related]
16. Single lung transplantation in rats with chemically induced pulmonary hypertension.
Kawaguchi AT; Mizuta T; Matsuda H; Shirakura R; Nakahara K; Tanaka H; Kawashima Y
J Thorac Cardiovasc Surg; 1992 Mar; 103(3):483-9. PubMed ID: 1532040
[TBL] [Abstract][Full Text] [Related]
17. Rosuvastatin, sildenafil and their combination in monocrotaline-induced pulmonary hypertension in rat.
Jasińska-Stroschein M; Owczarek J; Wesołowska A; Orszulak-Michalak D
Acta Pharm; 2014 Sep; 64(3):345-53. PubMed ID: 25296680
[TBL] [Abstract][Full Text] [Related]
18. The platelet thromboxane inhibitor, dazmegrel, does not reduce monocrotaline-induced pulmonary hypertension.
Langleben D; Carvalho AC; Reid LM
Am Rev Respir Dis; 1986 May; 133(5):789-91. PubMed ID: 3085563
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of compensatory right ventricular hypertrophy and heart failure following monocrotaline-induced pulmonary vascular injury by the Na+-H+ exchange inhibitor cariporide.
Chen L; Gan XT; Haist JV; Feng Q; Lu X; Chakrabarti S; Karmazyn M
J Pharmacol Exp Ther; 2001 Aug; 298(2):469-76. PubMed ID: 11454907
[TBL] [Abstract][Full Text] [Related]
20. Single lung transplantation in rats with fatal pulmonary hypertension.
Kawaguchi AT; Kawashima Y; Mizuta T; Ishibashi-Ueda H; Kanosue K; Shirakura R; Matsuda H
J Thorac Cardiovasc Surg; 1992 Sep; 104(3):825-9. PubMed ID: 1387440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
